Daplyza Tablets 10Mg (1 Strip = 7 Tablets)

Requires Prescription (YES/NO)

Yes

Generics

Dapagliflozin 

Used For

Diabetes

How it works

Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

Dosage

Dapagliflozin 

Side Effects

Infections and infestations : Common: Vulvovaginitis, balanitis and related genital infections, Urinary tract infection (including pyelonephritis and urosepsis) Uncommon: Fungal infection Metabolism and nutrition disorders . Very common: Hypoglycaemia (when used with sulphonylurea or insulin) Uncommon: Volume depletion, Thirst Rare: Diabetic ketoacidosisNervous system disorders : Common: DizzinessGastrointestinal disorders : Uncommon: Constipation, Dry mouth Skin and subcutaneous tissue disorders Common: Rash Musculoskeletal and connective tissue disorders : Common: Back pain Not Known: Fracture of BoneRenal and urinary disorders Common: Dysuria, Polyuria Uncommon: Nocturia, Renal impairmentReproductive system and breast disorders Uncommon: Vulvovaginal pruritus, Pruritus genital

Drug Interactions

ACE inhibitors , Flouroquinolones , Somatostatin Analogues , SGLT2 inhibitors

Indication

It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

When not to Use

Contraindications : History of a serious hypersensitivity reaction to dapagliflozin.Severe renal impairment, end-stage renal disease (ESRD), or patients on dialysis.

Precaution

It causes intravascular volume contraction. Symptomatic hypotension can occur after initiating dapagliflozin particularly in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m2), elderly patients, or patients on loop diuretics. Before initiating dapagliflozin in patients, volume status should be assessed and corrected. Monitor for signs and symptoms of hypotension after initiating therapy.

Warning 1

Insulin and insulin secretagogues are known to cause hypoglycemia. It can increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with Dapagliflozin.

Warning 2

It should not be used in patients with active bladder cancer. In patients with prior history of bladder cancer, the benefits of glycemic control versus unknown risks for cancer recurrence with dapagliflozin should be considered.

Warning 3

It increases the risk of genital mycotic infections. Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections.

Pregnancy category

Always consult your physician before using any medicine.

Storage (YES/NO)

Store this medicine at room temperature, away from direct light and heat.